Cargando…

The Search for Cost-Effective Treatment of Chronic Hepatitis B

Detalles Bibliográficos
Autores principales:	Smith, Vanessa E., Bruno, Christine J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2008
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437586/ https://www.ncbi.nlm.nih.gov/pubmed/18240883 http://dx.doi.org/10.18553/jmcp.2008.14.1.61

Ejemplares similares

Cost-Effective Pharmacologic Therapies to Treat Chronic Hepatitis B: How Far Have We Really Come?
por: Holbrook, Michelle
Publicado: (2008)

Functional cure of chronic hepatitis B – predictable?
por: Gerlich, Wolfram
Publicado: (2021)

Potential clinical application of RNAi‐based therapeutic strategies for treatment of chronic hepatitis B
por: Zhaori, Getu
Publicado: (2018)

In search of cost-effective and non-invasive biomarkers of traumatic brain injury
por: Daneshvar, Daniel H., et al.
Publicado: (2022)

Safety and efficacy of two-step peginterferon α-2a treatment in patients of chronic hepatitis B with acute exacerbation
por: Chen, C-C, et al.
Publicado: (2012)

Management of chronic hepatitis B patients: Efficacy & limitation of nucleos(t)ide analogues
por: Inoue, Jun, et al.
Publicado: (2011)

Pre-treatment HIV drug resistance testing cost-effectiveness
por: van de Vijver, David AMC, et al.
Publicado: (2020)

Frequency-dependent selection drives HBeAg seroconversion in chronic hepatitis B virus infection
por: Warner, Brook G., et al.
Publicado: (2013)

Activated protein C: cost-effective or costly?
por: Brar, Savtaj Singh, et al.
Publicado: (2007)

Mind the costs, too: towards better cost-effectiveness analyses of PBF programmes
por: Chi, Y-Ling, et al.
Publicado: (2018)

Under one roof: identification, evaluation, and treatment of chronic hepatitis C in addiction care
por: Martin, Stephen A., et al.
Publicado: (2018)

Application of Bayesian Approach to Cost-Effectiveness Analysis of Antiviral Treatments in Chronic Hepatitis B
por: Zhang, Hua, et al.
Publicado: (2016)

Functional cure of hepatitis B requires silencing covalently closed circular and integrated hepatitis B virus DNA
por: Ghany, Marc G., et al.
Publicado: (2022)

Cost-effectiveness of chronic hepatitis C screening and treatment
por: Lee, Hye Won, et al.
Publicado: (2022)

Challenges in synthesising cost-effectiveness estimates
por: Shields, Gemma E., et al.
Publicado: (2020)

Highlights: B-chronic lymphocytic leukemia: Current diagnostic characteristics of and treatments for chronic lymphocytic leukemia in Japan
por: Aoki, Sadao
Publicado: (2020)

Management of hepatitis B in the era of checkpoint inhibition
por: Dutcher, Janice
Publicado: (2020)

Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China
por: Toy, Mehlika, et al.
Publicado: (2015)

Issues of cost-benefit and cost-effectiveness for simulation in health professions education
por: Maloney, Stephen, et al.
Publicado: (2016)

Cost-effectiveness analysis for clinicians
por: Hill, Suzanne R
Publicado: (2012)

The cost-effectiveness challenge: is it worth it?
por: Knapp, Martin
Publicado: (2015)

An “Orphan” in search of a treatment: Pulmonary alveolar microlithiasis
por: Tendolkar, Manjit Sharad
Publicado: (2019)

HIV CTL escape: at what cost?
por: Smith, Stephen M
Publicado: (2004)

Aspirin, chronic hepatitis B (CHB) and hepatocellular carcinoma (HCC)—will there ever be enough data?
por: Crane, Harry, et al.
Publicado: (2023)

Hepatitis B Virus Genotype C is Predominant in Myanmar
por: Nwe Win, Nan, et al.
Publicado: (2017)

Is hepatitis B birth dose vaccine needed in Africa?
por: Tamandjou, Cynthia Raissa, et al.
Publicado: (2017)

Cost-effectiveness of phosphate binders among patients with chronic kidney disease not yet on dialysis: a long way to go
por: Rizk, Rana
Publicado: (2016)

Distributional Cost-Effectiveness Analysis Comes of Age
por: Cookson, Richard, et al.
Publicado: (2021)

Delayed introduction of the birth dose of Hepatitis B vaccine in EPI programs in East Africa: a missed opportunity for combating vertical transmission of Hepatitis B
por: Bodo, Bongomin, et al.
Publicado: (2017)

Search for effective treatments in patients with advanced refractory melanoma continues: can novel intratumoral therapies deliver?
por: Najjar, Yana G
Publicado: (2021)

Cost-effectiveness of combination antiviral treatment with extended duration for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B in China
por: Li, Runqin, et al.
Publicado: (2021)

Commentary: Evaluating affordability, cost-effectiveness, cost-utility, health economics, and incremental cost-effectiveness ratio of manual small-incision cataract surgery - The need of the hour
por: Tejaswini, Antarvedi, et al.
Publicado: (2022)

Costs and benefits of influenza vaccination: more evidence, same challenges
por: Ciancio, Bruno Christian, et al.
Publicado: (2014)

Hepatitis B prevalence in pregnant women in China: Progress and realities
por: Dusheiko, Geoffrey
Publicado: (2021)

Cost-effectiveness analysis of oral anti-viral drugs used for treatment of chronic hepatitis B in Turkey
por: Kockaya, Guvenc, et al.
Publicado: (2015)

Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance
por: Wang, Guiliang, et al.
Publicado: (2015)

Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluation
por: Zhang, Sihui, et al.
Publicado: (2023)

Access to high cost medicines in Australia: ethical perspectives
por: Lu, Christine Y, et al.
Publicado: (2008)

The Economic Costs of Diabetes: Is It Time for a New Treatment Paradigm?
por: Herman, William H.
Publicado: (2013)

Staying Connected: Transcriptomics in the Search for Novel Diabetic Kidney Disease Treatments
por: Terker, Andrew S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mrajbcu9tjbg3na9n6vbn39ftg